Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors

Eusebio S. Pires; Ryan S. D’Souza; Marisa A. Needham; Austin K. Herr; Amir A. Jazaeri; Hui Li; Mark H. Stoler; Kiley L. Anderson-Knapp; Theodore Thomas; Arabinda Mandal; Alain Gougeon; Charles J. Flickinger; David E. Bruns; Brian A. Pollok; John C. Herr

doi:10.18632/oncotarget.15755

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors

Eusebio S. Pires _, Ryan S. D’Souza, Marisa A. Needham, Austin K. Herr, Amir A. Jazaeri, Hui Li, Mark H. Stoler, Kiley L. Anderson-Knapp, Theodore Thomas, Arabinda Mandal, Alain Gougeon, Charles J. Flickinger, David E. Bruns, Brian A. Pollok and John C. Herr

PDF | How to cite

Oncotarget. 2017; 8:16099-16099. https://doi.org/10.18632/oncotarget.15755

Metrics: PDF 1660 views | ?

Present: The currently listed corresponding author, John C. Herr, is deceased. Oncotarget wishes to express our condolences to his family and colleagues.

Corrected: The new correspondence author information is as follows.

Original article: Oncotarget. 2015; 6(30):30194-211. DOI: 10.18632/oncotarget.4734

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15755

Publication Alerts

Corrections:

Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors